FDA Eyes Inspectional Form Changes As SOP Troubles Top FDA-483 Citations In 2013
This article was originally published in The Silver Sheet
Executive Summary
The way inspectional observations are presented on FDA-483 forms might be modified under a new FDA pilot program. The goal is to help device companies prioritize corrective actions to avoid potentially serious quality system troubles. The agency decided it was time to reassess how its investigators list observations on the forms after talking with industry device quality experts. The potential change comes at a time when FDA issued a record number of FDA-483s to firms last year, many of which indicated problems with procedures in a variety of quality system areas.
You may also be interested in...
Analysis: Foreign Firms Hit With Majority Of FDA Quality-Linked Warning Letters Last Year
Most of the 150 warning letters issued by FDA last year were sent to foreign manufacturers, a “Silver Sheet” analysis shows. That letters to overseas companies have outpaced those to domestic ones is a surprise given that the agency performs nearly four times as many inspections of U.S.-based facilities each year. But the foreign warning letter increase in 2013 might actually be a sign that FDA’s enhanced focus on overseas compliance in recent years has begun paying dividends. In related warning letter trends, CAPA has supplanted complaint handling as the No. 1 deficiency area cited in letters. Further, 56 close-out letters were sent to firms in 2013, down slightly from 2013.
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.